Cancer immunotherapy has revolutionized treatment of many forms of cancer by unleashing the
response against tumors. Immunotherapies that block checkpoint receptors like PD-1,
that limit the capacity of T cells to attack tumors, have become the choice for the treatment of numerous types of solid cancer. However, the introduction of PD-1-blocking agents can often result in T cells attacking healthy tissues in addition to cancer cells, causing severe, sometimes life-threatening, side effects that can blunt the benefits of immunotherapy.
The study was published in the journal Nature.
“While we know why blocking checkpoint receptors boosts anti-cancer immune responses, we don’t understand why these immunotherapies also cause adverse events in normal organs,” the authors write.
Advertisement
Currently doctors are not able to predict which individuals are likely to develop such side effects and which healthy organs will be attacked as a consequence of immunotherapy. Side effects may prompt doctors to either suspend immunotherapy or prescribe immunosuppressants, with negative consequences on the anti-cancer effects of immunotherapy.
For the study, a team led by Martina Damo, an associate research scientist in the Joshi lab, developed new generation mouse models to address the role of PD-1 in preventing T cells from attacking healthy skin. They mimicked immunotherapy by blocking PD-1 and found mice developed some of the same skin disorders observed in cancer patients treated with PD-1 blockers.
The data in mice were corroborated by analysis of skin biopsies obtained from cancer patients under treatment at the Yale Onco-Dermatology Program at Smilow Cancer Hospital at Yale New Haven, which is directed by Dr. Jonathan Leventhal.
“Our data in mice and humans support the hypothesis that checkpoint receptors like PD-1 function as gatekeepers of tissue homeostasis by allowing the presence of functional T cells in peripheral tissues without immunopathology,” Damo said. “We propose that PD-1-blocking immunotherapies interfere with these physiological regulatory functions, thus resulting in adverse events. This study lays the ground for the future development of improved immunotherapies that avoid adverse events.”
Reference :
- PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens – (https://www.nature.com/articles/s41586-023-06217-y)
Source: Eurekalert
Source link
#Exploring #Benefits #Immunotherapy #Cancer #Patients
